Finland, Jan. 28 -- Finland based Novartis Finland Oy has secured contract from HUS Group, the joint authority for Helsinki and Uusimaa for Pharmaceutical products - Tisagenlekleusel preparation (Kymriah) for pediatric patients or young adult patients aged 25 or older. The value of the contract is worth 200000000 EUR.
Published by HT Digital Content Services with permission from Pivotal Sources....